← Patent-cliff monitor small molecule OXBRYTA VOXELOTOR
Loss of exclusivity December 2036 latest FDA-listed patent expiry
Company GLOBAL BLOOD THERAPEUTICS INC
Drug detail Brand name OXBRYTA Active ingredient VOXELOTOR Strength 300MG Dosage form TABLET, FOR SUSPENSION Route ORAL Modality Small molecule FDA approval December 2021 Marketing status DISCN
Listed patents Patent Expires Type 11020382 December 2036 use U-3134 11944612 December 2036 use U-3893 10722502 February 2035 product 11452720 February 2035 use U-3459 9447071 February 2035 substance, product 9248199 January 2034 use U-2715 9018210 November 2033 substance, product 10806733 December 2032 substance 10034879 December 2032 substance, product 10017491 December 2032 product
Regulatory exclusivity Code Expires ODE-394 December 2028 ODE* November 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.